List of Excipients in Branded Drug TIBSOVO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Servier Pharmaceutical LLC	TIBSOVO	ivosidenib	72694-617	CELLULOSE, MICROCRYSTALLINE	2035-03-13
Servier Pharmaceutical LLC	TIBSOVO	ivosidenib	72694-617	CROSCARMELLOSE SODIUM	2035-03-13
Servier Pharmaceutical LLC	TIBSOVO	ivosidenib	72694-617	FD&C BLUE NO. 2	2035-03-13
Servier Pharmaceutical LLC	TIBSOVO	ivosidenib	72694-617	HYPROMELLOSE	2035-03-13
Servier Pharmaceutical LLC	TIBSOVO	ivosidenib	72694-617	HYPROMELLOSE ACETATE SUCCINATE 06081224	2035-03-13

TIBSOVO Excipient Strategy and Commercial Opportunities for Ivosidenib

Last updated: September 24, 2026

TIBSOVO is an immediate-release, film-coated tablet containing 250 mg of ivosidenib. Its excipient system is conventional for a high-value oral oncology product: lactose monohydrate and microcrystalline cellulose provide bulk, crospovidone supports disintegration, magnesium stearate and colloidal silicon dioxide support manufacturing, and a hypromellose-based film coating provides protection and identification. The commercial opportunity is less likely to come from a novel excipient platform than from qualified alternate suppliers, lactose-free reformulation, improved swallowing formats, generic-ready excipient equivalence, and formulation patents around modified-release or combination products.

TIBSOVO is marketed by Servier Pharmaceuticals in the United States. The FDA-approved indications include relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation, newly diagnosed AML in specified patients, and previously treated IDH1-mutated cholangiocarcinoma. The product is a small-molecule drug, so future competition will come through abbreviated new drug applications rather than biosimilar applications.[1]

What excipients are used in TIBSOVO tablets?

The TIBSOVO 250 mg tablet uses a standard compressed-tablet core with a film coating. The FDA prescribing information identifies the following inactive ingredients:[1]

Excipient	Primary formulation role	Commercial relevance
Lactose monohydrate	Diluent and tablet-bulk agent	Creates an opportunity for lactose-free alternatives
Microcrystalline cellulose	Diluent, compressibility aid, dry binder	Important for tablet strength and low-dose content uniformity
Crospovidone	Superdisintegrant	Supports rapid tablet breakup
Magnesium stearate	Lubricant	Affects ejection force, dissolution and blending
Colloidal silicon dioxide	Glidant and flow aid	Supports powder flow and manufacturing consistency
Hypromellose acetate succinate	Film-forming or coating-related polymer	Can affect coating robustness and moisture protection
Polyvinyl alcohol	Film-coating polymer	Supports coating adhesion and appearance
Sodium lauryl sulfate	Wetting or surfactant component	May improve coating or dissolution behavior
Talc	Anti-tacking and coating aid	Supports film-coating process control
Titanium dioxide	Opacifier and colorant	Supports tablet appearance and light protection

The label identifies the product as a film-coated tablet. The listed excipients do not indicate a lipid formulation, enteric dosage form, osmotic system or long-acting delivery technology.[1]

How does the TIBSOVO formulation work?

TIBSOVO is an immediate-release oral solid dosage form. The formulation must provide reliable disintegration and dissolution while maintaining tablet strength during high-volume commercial manufacture.

The principal formulation functions are:

1. The lactose and microcrystalline cellulose provide tablet mass and compressibility.
2. Crospovidone promotes rapid tablet disintegration after ingestion.
3. Magnesium stearate controls friction during tablet compression and ejection.
4. Colloidal silicon dioxide improves powder flow and reduces blend-processing variability.
5. The coating polymers, talc, titanium dioxide and surfactant support a durable, identifiable film coating.

The formulation is commercially significant because ivosidenib is a potent active ingredient administered as a 250 mg tablet. The excipients must support content uniformity, tablet robustness and dissolution without creating excessive manufacturing complexity.

The prescribing information allows administration with or without food but warns against a high-fat meal because it increases ivosidenib exposure.[1] That food-effect profile limits the commercial value of a formulation that depends on high-fat coadministration to achieve exposure. A successful lifecycle product would likely target more predictable exposure, easier administration or improved adherence.

What excipient opportunities exist for TIBSOVO?

The strongest opportunities fall into five areas: lactose-free formulations, swallowing improvements, supply-chain substitution, dissolution control and specialty packaging.

Lactose-free TIBSOVO alternatives

Lactose monohydrate is a conventional pharmaceutical diluent, but it creates a potential differentiation path for patients with lactose intolerance, dairy-related restrictions or excipient sensitivity. A lactose-free formulation could replace lactose with combinations of:

• Mannitol
• Dibasic calcium phosphate
• Anhydrous calcium phosphate
• Pregelatinized starch
• Spray-dried microcrystalline cellulose
• Coprocessed cellulose-based excipients

The principal technical risk is that excipient substitution can change tablet hardness, friability, disintegration, dissolution and blend uniformity. A lactose-free product would require comparative pharmaceutical development and regulatory support. It would not automatically qualify as an interchangeable substitute for the branded product.

Swallowing and geriatric formulations

TIBSOVO is used in older adults, including newly diagnosed AML patients at least 75 years of age or patients with comorbidities that preclude intensive induction chemotherapy.[1] This population creates demand for improved swallowing characteristics.

Potential dosage forms include:

• Smaller tablets with a higher drug load
• Film-coated tablets with lower swallow resistance
• Orally disintegrating tablets
• Dispersible tablets
• Granules for suspension
• Liquid oral formulations
• Tablets designed for administration through feeding tubes

These products face a major constraint: the approved label instructs patients to swallow tablets whole and not split, crush or chew them.[1] A commercial product that changes the administration method would require new formulation development and regulatory review. Crushing or dispersing the existing product should not be treated as an established commercial alternative.

Excipient supplier qualification

The current excipient system uses widely available materials. That creates opportunities for dual sourcing and manufacturing resilience rather than for exclusive ingredient commercialization.

Potential supplier opportunities include:

Supply area	Opportunity
Microcrystalline cellulose	Alternate particle-size grades and low-moisture grades
Crospovidone	Equivalent disintegration performance with improved batch consistency
Magnesium stearate	Low-variability grades with controlled specific surface area
Colloidal silicon dioxide	Improved flow and reduced electrostatic behavior
Film-coating systems	Preformulated systems combining polymer, pigment and process aids
Lactose	Low-endotoxin, low-moisture and lactose-free replacement platforms

For an approved product, changing an excipient supplier can trigger comparability work, process validation and regulatory assessment. The opportunity is strongest for suppliers that can offer documented equivalence, global GMP capacity and stable particle-size or moisture specifications.

Dissolution and exposure control

Ivosidenib has clinically relevant food-effect considerations. Excipient selection can influence wetting, tablet breakup and dissolution, but a formulation that materially changes exposure would require careful pharmacokinetic evaluation.

Commercial development could focus on:

• Faster initial disintegration
• Reduced dissolution variability across pH conditions
• Lower sensitivity to gastric contents
• Improved tablet robustness without delayed release
• More consistent exposure in patients with impaired intake

A surfactant such as sodium lauryl sulfate can support wetting, but its concentration and interaction with the drug substance must be controlled. Excessive surfactant can affect tolerability, dissolution, coating performance and regulatory acceptability.

What formulation patents could protect an improved TIBSOVO product?

A new ivosidenib product could receive patent protection if it contains a genuinely differentiated formulation or manufacturing process. The most commercially relevant claim categories would include:

• A specific excipient ratio that improves dissolution or stability
• A lactose-free composition with defined performance limits
• A modified-release tablet
• A dispersible or orally disintegrating dosage form
• A liquid formulation with controlled precipitation
• A solid dispersion or particle-engineered form
• A formulation that reduces food-effect variability
• A manufacturing process that improves content uniformity or tablet hardness
• A package-and-product combination that controls moisture or degradation

A patent claiming only the use of common excipients at routine levels would face meaningful validity and obviousness risk. Stronger protection would require comparative data showing an unexpected technical effect, such as improved dissolution under fed and fasted conditions, enhanced stability, reduced impurity formation or improved bioavailability consistency.

What is the FDA regulatory status of TIBSOVO?

TIBSOVO is an FDA-approved prescription drug containing ivosidenib as the active ingredient. The product is approved as a 250 mg film-coated tablet.[1]

FDA milestone	Date	Regulatory significance
Relapsed or refractory AML approval	July 20, 2018	Initial U.S. approval for IDH1-mutated AML
Newly diagnosed AML approval in specified patients	May 2, 2019	Expanded treatment population
Previously treated, IDH1-mutated cholangiocarcinoma approval	August 25, 2021	Solid-tumor indication
Newly diagnosed AML with azacitidine in specified patients	2022	Expanded combination-treatment use

The FDA label identifies molecular testing requirements for selecting patients with susceptible IDH1 mutations. The product is therefore linked to companion diagnostic and genomic testing activity, although the excipient strategy is independent of the biomarker requirement.[1]

What is the Orange Book and generic-entry status of TIBSOVO?

TIBSOVO is an approved small molecule and is eligible for generic competition through the ANDA pathway. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. Differences in inactive ingredients are generally permitted if they do not affect safety, efficacy, quality or bioequivalence.

The relevant generic-entry issues are:

• Reference listed drug identification
• Orange Book patent listings
• Regulatory exclusivity
• Paragraph IV certifications
• Bioequivalence under the FDA’s ivosidenib product-specific requirements, if applicable
• Manufacturing and analytical control of the 250 mg tablet
• Potential patent disputes involving compound, formulation, method-of-use or crystalline-form claims

An ANDA applicant can use a different excipient system, but the alternative formulation must deliver comparable performance. A lactose-free generic could have commercial appeal, but it would still compete primarily on price, availability and payer access.

No biosimilar pathway applies because ivosidenib is a chemically synthesized small molecule rather than a biologic. The major regulatory risk is therefore generic substitution, not biosimilar interchangeability.

When could TIBSOVO lose exclusivity?

TIBSOVO’s loss-of-exclusivity timing depends on the interaction of patent expiration, FDA regulatory exclusivity, pediatric exclusivity and litigation outcomes. The controlling dates are listed in the FDA Orange Book and relevant patent records, which can change as listings are corrected, delisted or challenged.[2]

The main exclusivity scenarios are:

Scenario	Commercial effect
No ANDA challenge before patent expiry	Generic entry is delayed until applicable patent barriers expire
Paragraph IV certification	May trigger patent litigation and a potential 30-month stay
Successful patent challenge	Earlier generic approval or launch may become possible
Settlement agreement	Entry may occur on a negotiated date, subject to agreement terms
Formulation patent survives	A generic may launch with a design-around formulation
Method-of-use patent remains enforceable	Label carve-outs may limit use in protected indications

The most valuable branded exposure is likely concentrated in the AML and cholangiocarcinoma indications. A generic entrant may seek a section viii statement or a carve-out from patented methods of use rather than challenge every indication.

What patent litigation and settlement risks affect TIBSOVO?

The commercial risk is determined by the specific Orange Book-listed patents and any patent litigation filed after ANDA notices. A Paragraph IV notice can lead to district-court litigation by the listed patent owner or exclusive licensee. A 30-month stay may delay FDA approval, but it does not guarantee that a generic cannot launch after other legal or regulatory events.

Potential litigation positions include:

• Invalidity of the asserted compound patent
• Noninfringement through an alternative formulation
• Invalidity of formulation claims for obviousness
• Noninfringement of method-of-use claims through a label carve-out
• Patent-term or listing challenges
• Settlement with a defined generic launch date

Servier’s acquisition of Agios’s oncology assets gave Servier commercial control of TIBSOVO in the United States and other markets under the transaction structure announced in 2020.[3] Licensing and collaboration arrangements remain relevant because patent ownership, regulatory rights and commercial rights may be divided by territory or indication.

How strong is the TIBSOVO excipient and formulation estate?

The formulation estate appears technically conventional based on the approved label. Conventional excipients reduce manufacturing risk but also limit the defensibility of broad formulation claims.

Estate characteristic	Assessment
Excipient availability	Strong; ingredients are broadly sourced
Manufacturing complexity	Moderate to low
Supply-chain substitution	Feasible with comparability work
Formulation differentiation	Limited for the marketed tablet
Lactose-free opportunity	Commercially credible
Modified-release opportunity	Technically possible but requires new clinical and regulatory work
Generic design-around potential	Meaningful
Biosimilar exposure	None
Method-of-use exposure	Relevant because the product has multiple indications

The strongest defensible position would likely come from claims tied to a demonstrated performance advantage rather than from the use of standard excipients alone.

How does TIBSOVO compare with other IDH-targeted drugs?

TIBSOVO competes in a targeted oncology market that includes IDH-directed therapies and broader AML treatments. Its principal differentiation is oral administration, IDH1 targeting and use across AML and cholangiocarcinoma populations.

Product	Active ingredient	Target	Dosage form	Competition relevance
TIBSOVO	Ivosidenib	Mutant IDH1	Film-coated tablet	Generic and lifecycle-formulation risk
IDHIFA	Enasidenib	Mutant IDH2	Film-coated tablet	Competes in IDH-mutated AML but not as a direct substitute for IDH1
Standard AML regimens	Multiple agents	Various	Injectable and oral	Affect treatment sequencing and market access
Azacitidine combinations	Azacitidine plus targeted therapy	Various	Injectable/oral combination	Relevant to newly diagnosed AML treatment decisions

TIBSOVO’s excipient strategy has greater commercial value in adherence and administration than in novel drug delivery. The patient population favors simple, reliable oral dosing, while the food-effect warning creates room for exposure-consistency improvements.

What commercial opportunities exist for TIBSOVO excipients?

The most realistic opportunities are:

1. A lactose-free ivosidenib tablet for patients requiring alternative diluents.
2. A lower-swallow-resistance tablet for older adults.
3. A dispersible or liquid formulation for patients unable to swallow tablets.
4. Dual-source excipient qualification for Servier or contract manufacturers.
5. Film-coating systems with improved moisture protection and process efficiency.
6. Generic formulations designed around equivalent dissolution and a differentiated inactive-ingredient profile.
7. Packaging systems that improve tablet stability in oncology distribution channels.
8. Global formulations that accommodate regional excipient restrictions and supply conditions.

The opportunity size is linked to TIBSOVO’s oncology revenue, treatment duration, geographic expansion and generic-entry timing. Direct excipient revenue would be modest relative to ivosidenib product revenue, but a supplier that becomes qualified for a branded or generic formulation could obtain recurring, regulated-market volume.

Key Takeaways

• TIBSOVO is a 250 mg immediate-release, film-coated ivosidenib tablet.
• Its excipient system uses conventional materials, including lactose monohydrate, microcrystalline cellulose, crospovidone, magnesium stearate and film-coating polymers.
• The clearest formulation opportunity is a lactose-free or swallowing-optimized product.
• A modified-release, dispersible or liquid product would require new formulation development and regulatory support.
• Generic competition will proceed through the ANDA pathway, not biosimilar approval.
• Orange Book patents, Paragraph IV challenges, method-of-use claims and settlement terms will determine generic-entry timing.
• The marketed formulation is technically robust but offers limited protection from design-around competition unless supported by specific performance data.
• Excipient suppliers have the strongest near-term opportunities in alternate sourcing, coating systems, low-variability grades and generic formulation support.

FAQs

Can TIBSOVO tablets be crushed or split?

The FDA prescribing information instructs patients to swallow TIBSOVO tablets whole and not split, crush or chew them.[1]

Does TIBSOVO contain lactose?

Yes. Lactose monohydrate is listed as an inactive ingredient in the TIBSOVO tablet formulation.[1]

Is a lactose-free generic version of TIBSOVO possible?

Yes. An ANDA applicant may use different inactive ingredients if the product meets applicable pharmaceutical equivalence, bioequivalence, quality and safety requirements.

Does TIBSOVO require a biosimilar application?

No. Ivosidenib is a small-molecule active ingredient. A competing product would generally use the generic-drug pathway rather than the biosimilar pathway.

Can excipient changes create a new TIBSOVO patent?

Potentially. A new patent could protect a formulation with a novel composition or demonstrated technical advantage, but routine substitution of standard excipients would face significant patentability challenges.

References

1. U.S. Food and Drug Administration. (2024). TIBSOVO (ivosidenib) tablets, prescribing information. Servier Pharmaceuticals LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. Servier. (2020). Servier enters into definitive agreement to acquire Agios’ oncology business. Servier Pharmaceuticals.